A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
Authors
Keywords
-
Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 30, Issue 1, Pages 69-77
Publisher
SAGE Publications
Online
2015-12-09
DOI
10.1177/0269881115620460
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Placebo Response in Antipsychotic Clinical Trials
- (2014) Bret R. Rutherford et al. JAMA Psychiatry
- Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970–2010
- (2013) Ofer Agid et al. AMERICAN JOURNAL OF PSYCHIATRY
- Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
- (2013) Leslie Citrome et al. CNS SPECTRUMS
- Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo
- (2013) Stephen M. Stahl et al. JOURNAL OF CLINICAL PSYCHIATRY
- Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study
- (2013) Henry A. Nasrallah et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial
- (2013) Antony Loebel et al. SCHIZOPHRENIA RESEARCH
- Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study
- (2013) Antony Loebel et al. SCHIZOPHRENIA RESEARCH
- The evidence for illness progression after relapse in schizophrenia
- (2013) Robin Emsley et al. SCHIZOPHRENIA RESEARCH
- Long-term safety and tolerability of lurasidone in schizophrenia
- (2012) Leslie Citrome et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration
- (2012) Ni A. Khin et al. JOURNAL OF CLINICAL PSYCHIATRY
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
- (2012) Stefan Leucht et al. LANCET
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
- (2012) Masaaki Ogasa et al. PSYCHOPHARMACOLOGY
- Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
- (2011) Herbert Y. Meltzer et al. AMERICAN JOURNAL OF PSYCHIATRY
- The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults
- (2011) Kelly Posner et al. AMERICAN JOURNAL OF PSYCHIATRY
- A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment
- (2011) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic
- (2010) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Trial design issues and treatment effect modeling in multi-regional schizophrenia trials
- (2010) Yeh-Fong Chen et al. PHARMACEUTICAL STATISTICS
- Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
- (2010) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- Lurasidone in the Treatment of Acute Schizophrenia
- (2009) Mitsutaka Nakamura et al. JOURNAL OF CLINICAL PSYCHIATRY
- Schizophrenia, “just the facts” 4. Clinical features and conceptualization
- (2009) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?
- (2008) A. S. Kemp et al. SCHIZOPHRENIA BULLETIN
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now